Home > Research > Publications & Outputs > Direct treatment costs of HIV/AIDS in Portugal
View graph of relations

Direct treatment costs of HIV/AIDS in Portugal

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Direct treatment costs of HIV/AIDS in Portugal. / Perelman, Julian; Alves, Joana; Miranda, Ana Cláudia et al.
In: Revista de saúde pública, Vol. 47, No. 5, 10.2013, p. 865-872.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Perelman, J, Alves, J, Miranda, AC, Mateus, C, Mansinho, K, Antunes, F, Oliveira, J, Poças, J, Doroana, M, Marques, R, Teófilo, E & Pereira, J 2013, 'Direct treatment costs of HIV/AIDS in Portugal', Revista de saúde pública, vol. 47, no. 5, pp. 865-872. https://doi.org/10.1590/S0034-8910.2013047004598

APA

Perelman, J., Alves, J., Miranda, A. C., Mateus, C., Mansinho, K., Antunes, F., Oliveira, J., Poças, J., Doroana, M., Marques, R., Teófilo, E., & Pereira, J. (2013). Direct treatment costs of HIV/AIDS in Portugal. Revista de saúde pública, 47(5), 865-872. https://doi.org/10.1590/S0034-8910.2013047004598

Vancouver

Perelman J, Alves J, Miranda AC, Mateus C, Mansinho K, Antunes F et al. Direct treatment costs of HIV/AIDS in Portugal. Revista de saúde pública. 2013 Oct;47(5):865-872. doi: 10.1590/S0034-8910.2013047004598

Author

Perelman, Julian ; Alves, Joana ; Miranda, Ana Cláudia et al. / Direct treatment costs of HIV/AIDS in Portugal. In: Revista de saúde pública. 2013 ; Vol. 47, No. 5. pp. 865-872.

Bibtex

@article{f70c0f4b06ac433ca00a464bf68a76c9,
title = "Direct treatment costs of HIV/AIDS in Portugal",
abstract = "OBJECTIVE: To analyze the direct medical costs of HIV/AIDS in Portugal from the perspective of the National Health Service.METHODS: A retrospective analysis of medical records was conducted for 150 patients from five specialized centers in Portugal in 2008. Data on utilization of medical resources during 12 months and patients' characteristics were collected. A unit cost was applied to each care component using official sources and accounting data from National Health Service hospitals.RESULTS: The average cost of treatment was 14,277 €/patient/year. The main cost-driver was antiretroviral treatment (€ 9,598), followed by hospitalization costs (€ 1,323). Treatment costs increased with the severity of disease from € 11,901 (> 500 CD4 cells/µl) to € 23,351 (CD4 count ≤ 50 cells/ µl). Cost progression was mainly due to the increase in hospitalization costs, while antiretroviral treatment costs remained stable over disease stages.CONCLUSIONS: The high burden related to antiretroviral treatment is counterbalanced by relatively low hospitalization costs, which, however, increase with severity of disease. The relatively modest progression of total costs highlights that alternative public health strategies that do not affect transmission of disease may only have a limited impact on expenditure, since treatment costs are largely dominated by constant antiretroviral treatment costs.",
keywords = "Adult, Aged, Female, HIV Infections, Health Care Costs, Humans, Male, Middle Aged, Portugal, Retrospective Studies",
author = "Julian Perelman and Joana Alves and Miranda, {Ana Cl{\'a}udia} and Ceu Mateus and Kamal Mansinho and Francisco Antunes and Joaquim Oliveira and Jos{\'e} Po{\c c}as and Manuela Doroana and Rui Marques and Eug{\'e}nio Te{\'o}filo and Jo{\~a}o Pereira",
year = "2013",
month = oct,
doi = "10.1590/S0034-8910.2013047004598",
language = "English",
volume = "47",
pages = "865--872",
journal = "Revista de sa{\'u}de p{\'u}blica",
issn = "1518-8787",
publisher = "University of Sao Paolo",
number = "5",

}

RIS

TY - JOUR

T1 - Direct treatment costs of HIV/AIDS in Portugal

AU - Perelman, Julian

AU - Alves, Joana

AU - Miranda, Ana Cláudia

AU - Mateus, Ceu

AU - Mansinho, Kamal

AU - Antunes, Francisco

AU - Oliveira, Joaquim

AU - Poças, José

AU - Doroana, Manuela

AU - Marques, Rui

AU - Teófilo, Eugénio

AU - Pereira, João

PY - 2013/10

Y1 - 2013/10

N2 - OBJECTIVE: To analyze the direct medical costs of HIV/AIDS in Portugal from the perspective of the National Health Service.METHODS: A retrospective analysis of medical records was conducted for 150 patients from five specialized centers in Portugal in 2008. Data on utilization of medical resources during 12 months and patients' characteristics were collected. A unit cost was applied to each care component using official sources and accounting data from National Health Service hospitals.RESULTS: The average cost of treatment was 14,277 €/patient/year. The main cost-driver was antiretroviral treatment (€ 9,598), followed by hospitalization costs (€ 1,323). Treatment costs increased with the severity of disease from € 11,901 (> 500 CD4 cells/µl) to € 23,351 (CD4 count ≤ 50 cells/ µl). Cost progression was mainly due to the increase in hospitalization costs, while antiretroviral treatment costs remained stable over disease stages.CONCLUSIONS: The high burden related to antiretroviral treatment is counterbalanced by relatively low hospitalization costs, which, however, increase with severity of disease. The relatively modest progression of total costs highlights that alternative public health strategies that do not affect transmission of disease may only have a limited impact on expenditure, since treatment costs are largely dominated by constant antiretroviral treatment costs.

AB - OBJECTIVE: To analyze the direct medical costs of HIV/AIDS in Portugal from the perspective of the National Health Service.METHODS: A retrospective analysis of medical records was conducted for 150 patients from five specialized centers in Portugal in 2008. Data on utilization of medical resources during 12 months and patients' characteristics were collected. A unit cost was applied to each care component using official sources and accounting data from National Health Service hospitals.RESULTS: The average cost of treatment was 14,277 €/patient/year. The main cost-driver was antiretroviral treatment (€ 9,598), followed by hospitalization costs (€ 1,323). Treatment costs increased with the severity of disease from € 11,901 (> 500 CD4 cells/µl) to € 23,351 (CD4 count ≤ 50 cells/ µl). Cost progression was mainly due to the increase in hospitalization costs, while antiretroviral treatment costs remained stable over disease stages.CONCLUSIONS: The high burden related to antiretroviral treatment is counterbalanced by relatively low hospitalization costs, which, however, increase with severity of disease. The relatively modest progression of total costs highlights that alternative public health strategies that do not affect transmission of disease may only have a limited impact on expenditure, since treatment costs are largely dominated by constant antiretroviral treatment costs.

KW - Adult

KW - Aged

KW - Female

KW - HIV Infections

KW - Health Care Costs

KW - Humans

KW - Male

KW - Middle Aged

KW - Portugal

KW - Retrospective Studies

U2 - 10.1590/S0034-8910.2013047004598

DO - 10.1590/S0034-8910.2013047004598

M3 - Journal article

C2 - 24626490

VL - 47

SP - 865

EP - 872

JO - Revista de saúde pública

JF - Revista de saúde pública

SN - 1518-8787

IS - 5

ER -